Pharmaceutical composition for treating damage by non-lethal irritants

FIELD: medicine.

SUBSTANCE: spray composition contains, wt/vol %: lidocaine hydrochloride 1.0-10.0; benzethonium chloride 5.0·10-4 - 5.0·10-3; sodium chloride 0.1-10.0; water for injections to 100 ml.

EFFECT: use of the declared composition is effective for treating damages by non-lethal irritants.

1 ex

 

The present invention relates to medicine, namely to the pharmaceutical industry, specifically, to the production of pharmaceuticals for the treatment of lesions of non-lethal means annoying. The main active drug compound of the proposed pharmaceutical composition is lidocaine.

Lidocaine belongs to local anesthetics (blocks voltage gated sodium channels, which prevents the generation of pulses in the endings of sensory nerves and conduction of impulses in nerve fibers), anti-arrhythmic drugs. Lidocaine in the local application expands the blood vessels, has no local irritation. It comes in the form of liquid solutions 0,25, 0,5, 1, 2, 4, 5 and 10%gel containing lidocaine 1-12,5%spray, containing 10% lidocaine, and plates containing lidocaine for intradermal injection. The term "lidocaine" in the patent and medical literature refers to both salts of lidocaine and its Foundation. In practical medicine, this term is used to indicate how the solutions of lidocaine and pharmaceutical compositions containing lidocaine.

In the proposed pharmaceutical composition and the experimental part, the term lidocaine describes lidocaine hydrochloride.

In practicesmedicine used injectable solutions or compositions, contains lidocaine. Thus, in particular, for the treatment of postinflammatory bullous keratopathy recommend a mixture of lidocaine 20-40 mg, dexason 4-8 mg, taufon 40-80 mg, dalargin 1-2 mg, lydasum 16-32 units act., distilled water 3-6 ml [RF Patent №2218896];

- for the treatment and prevention of scar strictures of the esophagus after chemical burns using Alloplant, diluted in 2%solution of lidocaine [RF Patent №2269349];

- for the treatment of chronic pharyngitis conduct application anesthesia with 2%lidocaine solution, then enter a 1%solution of emoxipin [RF Patent №2281760];

- for the treatment of postoperative inflammatory complications after cataract extraction with implantation of an artificial lens is injected composition comprising lidocaine 20-40 mg, dalargin 1-2 mg, Mexidol 50-100 mg, hyaluronidase 16-32 Units, gamazo 3000-5000 ME [RF Patent №2290203];

- for the treatment of malignant exophthalmos thyrotoxicosis use a mixture of lidocaine and hydrocortisone [RF Patent №2294745];

- for the treatment of recurrent uveitis using a mixture of lidocaine 20-40 mg, Mexidol 50-100 mg, dalargin 1-2 mg, lydasum 16-32 UNITS, Gamesa 2500-5000 ME, as well as a mixture of lidocaine 30-50 mg, histogram (0,02%) 2-4 mg, lydasum 16-32 ED [RF Patent №2299065];

- for the treatment of primary open-angle glaucoma injected mixture: lidocaine 50-100 mg, histogram 10-20 mg aminophylline 12-24 mg, Glutoxim 5-10 mg, lydasum 16-32 Units [PA the UNT of the Russian Federation No. 2320308];

in the treatment of inflammatory and degenerative diseases of the nerves and musculoskeletal system is a solution for injection that contains the following ingredients: thiamine hydrochloride, pyridoxine hydrochloride, cyanocobalamin, lidocaine hydrochloride, sodium hydroxide, benzathine chloride, Trilon B, and water for injection [RF Patent №2326669];

- for the treatment of subepithelial flair of the cornea after photorefractive keratectomy using medicinal mixture containing 30-50 mg of lidocaine, 16-32 Units lidz, 2-4 mg histogram, 0.5-1.0 mg of dalargin [RF Patent №2343885] etc.

Under terminal anesthesia of mucous membranes (in dentistry, in the preparation and endoscopic studies) use not more than 2 ml of 10% solution of lidocaine; anesthesia of mucous membranes (if intubation, broncho esophagoscopy, the removal of polyps and other) using 1-2% solutions, less 5% lidocaine. In ophthalmic practice for conducting wire, infiltration and surface anesthesia, most often buried 2-4% lidocaine solution into the conjunctival SAC of 2 drops 2-3 times (copy of standard clinical and pharmacological articles attached).

In recent years more and more attention of researchers attracted to such methods of using compositions containing lidocaine,: - transdermal route of administration, e.g. the measures RF patent №2376016, U.S. patent No. 6299902, 7695733, applications USA№№20090123527, 2009112072, 20100303753, 20110060309;

- inhalation method application in the form of an aerosol, for example, U.S. patent No. 543445, 5679325, application U.S. No. 20090004279 or

- in the form of a spray, for example, U.S. patent No. 5858331, the United Kingdom patent No. 839943, application U.S. No. 20090042968, 20100016402 etc.

The closest analogue of the proposed pharmaceutical composition is a pharmaceutical composition in the form of a spray for the treatment of wound surfaces [RF Patent №2416394 priority from 25.01.2010]. Renowned pharmaceutical composition comprises the active ingredient is lidocaine, additionally two active substances - atsemin and ofloxacin, preservative - nipagin, for receiving solution uses purified water. Renowned pharmaceutical composition in the form of spray is intended for the treatment of wound surfaces.

The present invention is the treatment of lesions of non-lethal means annoying.

The problem is solved in that in the proposed pharmaceutical composition in the form of a spray containing the active ingredient is lidocaine, preservative - benzathine chloride, water for injections is added sodium chloride, the ratio of ingredients, wt./vol. %:

Lidocaine hydrochloride 1,0-10,0
Benzathine chloride5,0·10-4-5,0·10-3
Sodium chloride0,1-10,0
Water for injectionto 100 ml

Distinctive features of the proposed pharmaceutical compositions are using the original ingredients (in the above ratio) and sodium chloride to create the optimum osmotic pressure of the composition.

Given the characteristics of the mucous membranes of the eyes, and subjected to the action of irritating the tools you will need the exact observance of the ratios of the original ingredients. The use of lidocaine below the lower limit does not guarantee the occurrence of the desired effect in the case of a powerful irritant effect. When the concentration of lidocaine is more than 10% limited opportunities permitted use.

The final selection of concentrations was based on data from biological research.

The following examples illustrate but do not limit the claims of the applicants.

EXPERIMENTAL EXAMPLES

For the preparation of pharmaceutical compositions in the form of spray take about 70 ml of water for injection (FS 42-2620-97), in which dissolve the required amount of lidocaine GI is rochloride (ND 42-14192-06) (based on anhydrous substance), benzathine chloride (Fund 42-0067-5541-04 or. Heb. Pharm.), sodium chloride (mm 42-0474-4119-03 or Heb. Pharm.) and stirred for 15 minutes, bring up to the required volume with water for injection (FS 42-2620-97), filtered through a sterile filter 0,22 µm, is poured into a container equipped with a spray bottle, Packed in a plastic bag and sterilized by radiation.

On the basis of preliminary biological studies we have proposed in this patent pharmaceutical composition under the conditional name "lidocaine 4% in the form of spray" of the following composition:

Lidocaine hydrochloride (ND 42-14192-06)
(in terms of anhydrous substance)4.0 g
Benzathine chloride (Fund 42-0067-5541-04, Eurofarm.)2.0 mg
Sodium chloride (mm 42-0474-4119-03, Heb. Pharm.)0.6 g
Water for injection (FS 42-2620-97)to 100 ml

The study of the acute toxicity

Experimental studies have shown that the value of median lethal dose (LD50) if/W the introduction of the drug Lidocaine 4% in the form of a spray, on the basis of the content of the project for the active component in the solution, in rats of different sex range from 520 to 680 mg/kg inhalation introduction LD50in rats range from 430 to 480 mg/kg Lethal effects when intracrystalline medication 10000 mg/kg and cutaneous application of 20000 mg/kg were observed.

Inhalation introduction of purebred dogs at a dose of 16 mg/kg (10 times the maximum therapeutic dose for humans) does not cause any significant changes in the General condition, behavior, and structure of internal organs.

Consequently, the results of toxicomanie, necropsy data and observations of experimental animals in postintoksikatinom period of acute poisoning can take dosage form of the drug Lidocaine 4% in the form of spray" to class IV low-toxic drugs (N. Hodge et al., Clinical Toxicology of Commercial Products. Acute Poisoning. Ed. IV, Baltimore, 1975, 427 p.; Kid, 1973). The status of survivors of acute intoxication of the animals shows good tolerability and safety of the drug in doses exceeding therapeutic for a person dozens of times.

The study of subacute toxicity in inhalation routes of administration in rats

As a control drug was distilled water is used.

The spray nozzle was inserted in the mouth of an animal and do a set number of clicks. If the volume was previously installed, when one is pressed for one second sprayed approximately 70 mg (ál) the contents of a container.

The dose calculations were made based on the fact that the maximum daily dose for humans is 1.6 mg/kg or 20 single shots.

Therapeutic daily dose for rats was 1 respectively, or 14 mg/kg

1 dose of 14 mg/kg (exceeds the maximum daily human dose is approximately 10 times). This dose was received with one click on the spray nozzle.

2 dose of 140 mg/kg (100 times more than the maximum daily dose for humans). Received in ten clicks on the spray nozzle.

3 dose of 280 mg/kg (200 times more than the maximum daily dose for humans). Received at twenty clicks on the spray nozzle.

The second and third doses rats were treated for 4 hours by successive re-injection.

Dosing was carried out based on the active component of the drug. The drug was administered for 14 days. The total number of animals in the experiment: 100 male and 100 females weighing 170-200 g

Use of the drug "Lidocaine 4% in the form of spray in rats of both sexes inhalation once daily for 90 days at doses of 14, 140 and 280 mg/kg does not affect the appearance, General condition and behavior of animals; no negative effect on biochemical parameters of blood and the main Phi is Biologicheskie functions of the body; does not cause pathological changes, which indicates a good tolerability and low toxicity.

The study of subacute toxicity in inhalation route of administration for dogs

The dose calculations were made based on the fact that the maximum daily dose for humans is 1.6 mg/kg or 20 single shots.

Therapeutic daily dose for dog amounted to 2.8 mg/kg

1 dose of 2.8 mg/kg (exceeds the maximum daily human dose is about 2 times). This dose received by clicking on the spray nozzle 12-13 times (when the weight of the dog 12-13 kg).

2 dose - 14.0 mg/kg (10 times the maximum daily dose for humans). Received with 65 taps on the spray nozzle.

3 dose - 28.0 mg/kg (20 times the maximum daily dose for humans). Received at 130 clicks on the spray nozzle.

The second and third doses rats were treated for 4 hours by successive re-injection.

Dosing was carried out based on the active component of the drug.

Control - water

The frequency of introduction of 1 times a day for 14 days

The number of animals

1 dose: 3 males, 3 females;

2 dose: 3 males, 3 females;

3 dose: 3 males, 3 females;

Control: 3 males, 3 females

The total number of animals in this experiment - 24, 6 - control.

Dogs identificare is Alice by nicknames, the appearance and the number given after randomization, marked on the collar. Removal of trash produced daily. Accounting for the consumption of food, water, urine was performed in accordance with the programme of studies using metabolic cages. Once a day the animals received water at room temperature in a volume of 2 L. the body Weight of each animal was determined medical scales. Dynamics of body weight in dogs of all groups was the same. Every day spent observing the animals of all groups immediately after injection and at the end of the day.

During 28 days of study with daily inspection did not observe changes in the General condition of the animal experimental and control groups, which was estimated by the sum of the following parameters:

the position of the body in space - natural;

- build strong, average;

- the Constitution (exterior and interior features of animals) - coarse, dense, friable;

- temperament determined by observing the nature of the responses, was basically lively, excitable;

- fatness is good and satisfactory.

Objective: - the Condition of the upper respiratory tract and chest satisfactory. The number of respiratory movements 14-18 per minute. Violations of the strength of the respiratory movements and their symmetry is not detected. The rhythm of the breath to sigh , on the exhale - 1.6. Auscultation behind the shoulder region on the inhale auditioned vesicular breathing. Wheeze was not. The mucosa of the oral cavity had a pale pink color, some dogs have been pigmented. In the control group mucosa of the mouth was wet, in the groups treated with the drug, the mucosa was dry. This effect lasted 30-40 minutes after the last injection of the drug. When viewed limb injuries, wounds, presence of puffiness not found. The coloration of auricles was pale pink, signs of inflammation, discharge from the ears was not. Hearing loss is not observed.

Inhalation drug "Lidocaine 4% in the form of spray" dogs of both sexes at doses, the maximum of which exceeds therapeutic dose for a person 20 times, does not lead to the development of pathological changes of the General condition and behavior of animals, no significant toxic effects on cardiovascular activity, morphological composition, biochemical, and other indicators of peripheral blood and bone marrow, on the functional state of the liver and kidneys, protein, carbohydrate, fat and electrolyte types of metabolism.

The study of subacute toxicity upon skin application in experiments on rats

This study aimed at establishing security mnogokrat the CSOs cutaneous drug application "Lidocaine 4% in the form of spray.

Was used cutaneous introduction, because it is how you plan to drug the man.

The day before the start of the study on the back of the rats were removed woolen cover on a plot size of 2.5×2.5 cm method trimanganese (plucking) under ketamine anesthesia (V/m 30 mg/kg). In rabbits was vestigal woolen cover on a plot size of 15.0×10.0 see In subsequent growing wool six animals were regularly cut on average after 4 days, when this was scarificial skin.

As a control drug was distilled water is used.

The dose calculations were made based on the fact that the maximum daily dose for humans is 1.6 mg/kg or 20 single shots.

Therapeutic daily dose for rats was 1 respectively, or 14 mg/kg

1 dose of 14 mg/kg (exceeds the maximum daily human dose is approximately 10 times). This dose was received with one click on the spray nozzle.

2 dose of 140 mg/kg (100 times more than the maximum daily dose for humans). Received in ten clicks on the spray nozzle.

3 dose of 280 mg/kg (200 times more than the maximum daily dose for humans). Received at twenty clicks on the spray nozzle.

The second and third doses rats were treated for 4 hours by successive re-injection.

Dosing is sushestvovali based on the active component of the drug. The total number of animals in the experiment: 100 male and 100 females weighing 180-190,

Daily cutaneous application of medication Lidocaine 4% in the form of a spray in three ranges of doses for 14 days in rats of both sexes did not cause irritation, inflammation or destruction of the skin or subcutaneous tissue, disorders of hair follicles and was not accompanied by the development of dystrophic and destructive, focal sclerotic changes in parenchymatous cells and stroma of the internal organs of rats.

The study of subacute toxicity upon skin application in experiments on rabbits

The day before the start of the study on the back of the rabbits was vestigal woolen cover on a plot size of 15.0×10.0 see In subsequent growing animal hair regularly trimmed on average after 4 days, when this was scarificial skin.

As a control drug was distilled water is used.

1 dose of 2 mg/kg (equivalent to the maximum daily human dose). This dose was received with two taps on the spray nozzle.

2 dose of 10 mg/kg (6 times the maximum daily dose for humans). Received in ten clicks on the spray nozzle.

3 dose of 30 mg/kg (20 times the maximum daily dose for humans). Received at thirty clicks on the spray nozzle.

The second and third doses of the rollers are received within 1 hour by successive re-pressings.

Dosing was carried out based on the active component of the drug. The total number of animals in the experiment: 25 males and 25 females weight 2300-2500,

It is shown that daily use of the drug "Lidocaine 4% in the form of a spray in three ranges of doses for 14 days in rabbits of both sexes does not cause irritation, inflammation or destruction of the skin, and is not accompanied by the development of dystrophic and destructive, focal sclerotic changes in parenchymatous cells and stroma of the internal organs of rabbits.

The study of subacute toxicity in intracrystalline the introduction of rats

Daily therapeutic dose for humans is 0.6 ml or 1-2 drop in each eye 1-3 times or 12 drops per day. The maximum therapeutic dose for the average human weighing 60 kg would be 0.01 ml/kg According to the rules of extrapolation therapeutic dose for rodents 5.7 times more than for a person who is 0,057 ml/kg (0,006 ml/100 g). This is the first therapeutic dose were dosed out drops using an automatic micropipette. Accordingly counted and subsequent doses: three - and ten-fold.

The frequency of application of 1 times a day for 14 days.

The duration of the observation

The total duration of follow - up 28 days.

After injection the animals of all groups were scored for us what RowKey ether and aimed at autopsy or postmortem examination.

The General condition was estimated by daily inspection of the animal.

Weighing, consumption of water and feed were performed once a week and at the end of the observation period.

Physiological parameters were recorded before the start of the experiment (background), 14 days (on day 15 of the experiment) and 28 day.

Hematological and biochemical parameters were evaluated at 15 and 28 day study.

Macroscopic and histological examination of internal organs was performed posthumously after the introduction and at the end of the observation period.

The total number of animals in the experiment: 100 male and 100 females weighing 180-190,

Daily application of the model sample of the drug Lidocaine 4% in the form of a spray in three ranges of doses for 7 days in rats of both sexes did not cause irritation, inflammation or destruction the eye tissues, and was not accompanied by the development of dystrophic and destructive, focal sclerotic changes in parenchymatous cells and stroma of internal organs.

The study of subacute toxicity in intracrystalline the introduction of rabbits

Therapeutic dose for rabbits (weighing up to 3 kg) approximately 0.03 ml/kg release Form of the drug, manufactured by NPC "parsedata water solution to spray in the form of inhaler. Dosing volume with one click is of 0.07 ml, With an account of the m possible dosing model sample and the maximum therapeutic dose for rabbits decided to consider the first dose is 1 spray (0,07 ml) in the conjunctival cavity of the eye. Accordingly counted and subsequent doses: three - and ten-fold.

The duration of observation, the total duration of follow - up 28 days.

After injection the animals of all groups were scored overdose

ether and aimed at autopsy or postmortem examination.

The General condition was estimated by daily inspection of the animal.

Weighing, consumption of water and feed were performed once a week and at the end of the observation period.

Physiological parameters were recorded before the start of the experiment (background), 14 days (on day 15 of the experiment) and 28 day.

Hematological and biochemical parameters were evaluated at 15 and 28 day study.

Macroscopic and histological examination of internal organs was performed posthumously after the introduction and at the end of the observation period.

The total number of rabbits in the experiment: 25 males and 25 females weight 2300-2500,

Daily use of the drug "Lidocaine 4% in the form of a spray in three ranges of doses for 14 days in rabbits of both sexes does not cause irritation, inflammation or destruction the eye tissues, and is not accompanied by the development of dystrophic and destructive, focal sclerotic changes in parenchymatous cells and stroma of the internal organs of rabbits.

Evaluation of the effectiveness of the solution Lidocai the and 4% in the form of a spray when intracrystalline application

Efficiency evaluation of Lidocaine 4% in the form of a spray when intracrystalline application was conducted on rabbits breed "Chinchilla". All animals were divided into two groups without treatment (1) treatment (2). Damage to the eyes of experimental animals (rabbits) was modeled by the installation in the conjunctival SAC of the eye using a micropipette drops with a volume of 0.02 ml, containing 0.6 mg of lacrimator - morpholide pelargonii acid (IPC). The working solution was prepared from a mixture containing 70% of the IPC in ethanol. The concentration of the IPC in the working solution was 3%. Evaluation of the effectiveness of treatment of eye medication Lidocaine 4% in the form of a spray through two spray after 5 min after exposure of irritant 2 spray and re-spray after 15 minutes Left eye served as control. Observation of the animals was carried out within 14 days.

During the experiment it was established that in the first day after exposure IPC status of the mucous membranes of the eyes of rabbits did not differ. The duration of anesthesia on the background exposure to irritating substances was up to 15-25 minutes, it Should be noted a more rapid decrease in severity of watery eyes in group 2. Further marked subsidence of the inflammatory phenomena, while in group 1 symptoms of inflammatory reactions like redness and swelling of mucous membranes, were boliviarian. Since 3 days, 50% of the animals of the 1st group identified the symptoms of serous or sero-purulent conjunctivitis (the result of attaching a secondary infection). Test with fluorescein was positive in all animals within 2 days.

By the end of the observation period (14 days) full clinical recovery was recorded in all animals.

The total number of rabbits in the experiment: 25 males and 25 females weight 2300-2500,

Thus, despite the fact that when exposed to IPC revealed no organic damage to the cornea and recover on their own within 14 days, therapy early after exposure to irritating substances significantly accelerates the dynamics of the healing process.

As a result, it was obtained the following data: animals that received treatment immediately after exposure to irritant, noted the shortening of the inflammatory process up to 5-7 days. Whereas in group 1 (untreated) process recovery was delayed until 10 to 14 days, 50% of the animals observed a secondary infection in the form of a serous or sero-purulent conjunctivitis.

On the basis of SPbGU research Institute "geriatric medical-social centre" 40 volunteers established that the proposed pharmaceutical composition does not have a locally irritating, not provided the negative effects on vital signs: eye, hematological, biochemical parameters, has no effect on the cardiovascular system.

The proposed pharmaceutical composition extends the range of drugs produced in Russia, are available for consumers, doctors and patients.

The proposed pharmaceutical composition in the form of a spray for the treatment of lesions of non-lethal means annoying planned production of the Federal state unitary enterprise Scientific-production center "parsedata" Federal medical-biological Agency in accordance with the technological regulations and pharmacopoeial article of the enterprise.

Pharmaceutical composition in the form of a spray for the treatment of lesions of non-lethal irritant drugs containing active ingredient : lidocaine, a preservative and water, characterized in that as preservative use benzathine chloride and optionally introducing sodium chloride, the ratio of the ingredients of wt./vol.%:

lidocaine hydrochloride1,0-10,0
benzathine chloride5,0·10-4-5,0·10-3
sodium chloride0,1-10,0
to 100 ml



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely anaesthiology in ophthalmosurgery, and may be used in vitreoretinal surgeries, including those terminated by the stage of introducing silicone oil. For this purpose, 40-45 minutes before the operation, the retrobulbar introduction of a mixture of 2% lidocaine and 0.75% ropivacaine in proportions 1:1 in the amount of 4-5 ml is prescribed. It is followed by the intraoperative intravenous titration introduction of 0.01% nitroglycerine starting with 1 ml 1-2 minute before the introduction of silicone oil in response to a surgeon's signal. The nitroglycerine introduction is terminated when patient's systolic blood pressure becomes lower than the initial values by 10-20%.

EFFECT: method provides adequate anaesthesia combined with a reduced risk of developing complications due to blood pressure correction at the specific stage of surgery.

1 ex

FIELD: medicine.

SUBSTANCE: method involves the intramuscular introduction of the preparations Galavite 200 mcg/mouse and Lidocaine 8 mcg/kg of body weight once a day for three days running every 24 hours to experimental animals CBA line mice suffering a burning injury with underlying mycotic and bacterial infections accompanied by anti-infectious protection suppression.

EFFECT: invention enables creating a model of hospital strain formation which is applicable for studying the variations of the properties of opportunistic microorganisms to increasing virulence and antibiotic resistance.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely neurology, orthopaedics, reflexotherapy, physiotherapy exercises, recreation therapy and is applicable in integrated treatment of myofascial pain accompanying spine osteochondrosis. Pain management procedures are followed by a complex of exercises with using the HUBER apparatus consisting of seven staticodynamic exercises aimed at strengthening and activation of muscles of upper limb girdle, greater pectoral muscle, pelvic floor muscles and gluteal muscles. It is combined with loading and coordination improvement of left broadest muscle of back, left obliques, left lumbar quadrate muscle. Upper shoulder anchors, broadest muscle of back and rhomboid muscle are relaxed, and postural muscles are coordinated. Lumbar spine muscles are relaxed. Tone in upper extremity and back muscles is strengthened. It is followed by making exercises for activation of muscles of upper limb girdle, pectoral muscles, pelvic floor muscles, gluteal muscles. Then, the exercises for strengthening of lumbar muscles for the purpose of improving the body position coordination, relaxation of back ground of femoral and hip muscles, strengthening of abdominal wall muscles.

EFFECT: method improves support ability of feet, normalises position of the centre of gravity, forms an optimum motor conditions.

3 ex, 7 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to anesthesiology and thoracic surgery, and can be used as anesthetic aids in surgery on lung resection. For this purpose carried out is general anesthesia with microrelaxants and artificial lung ventilation in combination with blockades. Before anesthesis induction subpleural blockade is performed. After intubation of patient vagosympathetic blockade is carried out. As local anesthetic, in carrying out said blockades 0.2% ropivacaine solution is used.

EFFECT: method makes it possible to ensure adequate blockade of pain impulse at stages of transduction and transmission in carrying out operation on patients with reduced reserve heart possibilities.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to anesthesiology, and can be used where block brachial plexure anaesthesia required in upper extremity surgeries. For this purpose, a first needle stick point is arranged on a periphery edge of a subclavian artery 1 cm above a posteromedial edge of a clavicle. A second needle stick point is located in an axillary cavity below an axillary pulsation over a head of humerus.

EFFECT: method enables safe adequate block anaesthesia in appropriate surgeries due to additional ulnar nerve block.

2 ex

FIELD: chemistry.

SUBSTANCE: novel compound relates to amine derivatives of pyruvic acid amides and is biologically active - succinate of N-(2,4,6-trimethylphenyl) amide 2-(β-N,N-diethylamino ethylamino)-4-oxo-4-(4-methyl-phenyl)-2-butenoic acid of formula

.

EFFECT: compound has marked local anaesthetic and antimicrobial activity.

1 cl, 1 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely, to anaesthesia in dentistry, and can be used if maxillary anaesthesia is needed. For this purpose, in a region of an alveolar process of an upper jaw between juga alveolaria 12 and 13 or teeth 22 and 23 respectively depending on a side of the jaw, at level of a projection of root ends, intraosseous injection of an anaesthetic solution is performed.

EFFECT: method provides safe adequate maxillary anaesthesia ensured by blocking the conduction of peripheral branches of an infraorbital nerve due to spongy bone impregnation with the anaesthetic solution to penetrate into an infraorbital canal.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to traumatology and orthopedics and can be used in operations on Achilles tendon, ankle joint and foot. For this purpose block of tibial nerve is performed by introduction of anesthetic through point, located on the middle of the distance between internal ankle and internal edge of Achilles tendon. Additionally performed is block of common paroneal nerve by introduction of anesthetic through point, located behind fibular bone head.

EFFECT: method makes it possible to provide adequate anesthesia of foot for long term due to more accurate determination of reference points for additional block of paroneal nerve.

2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely, to anaesthesiology and dentistry, and can be used as an anaesthesia care of dental interventions. That is ensured by infiltration anaesthesia as follows. In the middle of each gingival papilla adjoining a tooth to be anaesthetised, a short-needle syringe is pricked in from a vestibular side at an angle 90 degrees to a surface of a mucous membrane of the medial and distal gingival papilla. The needle is moved forward firmly to a bone. Then an anaesthetic drug 0.2 ml of 4 % articaine and adrenaline of various concentrations is introduced from each side.

EFFECT: method provides the adequate and prolonged anaesthesia ensured by the most exact delivery of the anaesthetic drug and vasoconstrictive agent to nerve fibres.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely, surgical dentistry and maxillofacial surgery and can be used for treatment and prevention of alveolitis. Ointment for treatment and prevention of alveolitis contains lanolin-vaseline base, crystalline iodine, water solution of potassium iodide, solcoseryl dental adhesive paste, anesthesin, polysorb MP, distilled water, with the following component ratio: lanolin-vaseline ointment 40.5-42.5; crystalline iodine 0.1-0.3; water solution of potassium iodide 0.4-0.5; solcoseryl dental adhesive paste 40.5-42.5; anesthesin 3.8-5.8; polysorb MP 0.3-0.5; distilled water - the remaining part.

EFFECT: invention makes it possible to accelerate healing of bone wounds, prevent development of inflammatory complications and reduce period of recovery of patients with alveolitis.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of medicine, in particular, to antibacterial compositions. Invention discribes antibacterial composition, device, which contains said composition, method of bacteria destruction, inactivation of viruses, prevention and/or treatment and/or reduction of transmission of bacteria and virus-associated diseases, method of sanitary user's skin processing. Antibacterial composition contains a) from 0.5% to 15% of mixture of surface-active substances, which consist of amino-oxide surface-active substance and, at least, one non-anionic surface-active substance by weight of composition b) from 1% to 15% of mixture of pyroglutamic acid, succinic acid, by weight of composition c) from 15% to 85% of water by weight of composition, with composition being foaming. Composition is applied on place in safe and effective quantity and re-applied if necessary, making it possible for claimed composition to dry and remain on user's skin.

EFFECT: invention provides stable antibacterial composition, which ensures immediate and retained antibacterial activity without irritating skin.

20 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and represents a complex of nucleic acid and strongly branched cyclic dextrin representing glucan of a degree of polymerisation 50-5000, containing an internal branched cyclic structural fragment formed by alpha-1,4-glucoside bonds and at least one alpha-1,6-glucoside bonds and an external branched structural fragment bound to the internal branched cyclic structural fragment. The group of inventions also involves a composition containing of the diacylphosphatidylcholine, at least one compound specified in cholesterol, and a primary aliphatic amine, as well as the use and the method for cell delivery.

EFFECT: group of inventions provides low toxicity and high degree of safety; it is able to maintain the stable content of nucleic acid in a cell.

14 cl, 6 ex, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to enantiomerically pure (2S)- or (2R)-N,N,N-trimethyl-2,3-bis[[(9Z)-1-oxo-9-octadecenyl]oxy]-1-propanamide chloride (DOTAP chloride) which possess the transfection properties and can find application in medicine and pharmaceutics for intracellular transportation of pharmaceutically active compounds. The invention also refers to a pharmaceutical composition and the use of enantiomerically pure (2S)- or (2R)-DOTAP chloride as an ingredient for preparing drugs.

EFFECT: preparing the compounds which possess the transfection properties and can find application in medicine and pharmaceutics for intracellular transportation of pharmaceutically active compounds.

7 cl, 2 tbl, 6 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

EFFECT: preparation shows high activity.

6 cl, 1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmaceutics, and concerns a storage-stable composition in the form of nanoparticles of size 10-20 nm containing a fatty acid salt, phosphatidyl choline and maltose for the integration of biologically active substances, particularly, drugs, as well as drug compositions containing the fatty acid salt, phosphatidyl choline, maltose and a drug substance, and a method for preparing them.

EFFECT: development of the storage-stable composition.

4 cl, 5 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of liposomal preparative form for medical-cosmetic and external pharmacologic application. Liposomal nanocapsule represents hollow sphere, formed by two-layer lipid coating, which contains external and internal hydrophilic layers, which include water extract of peloids, between which placed is hydrophobic area of two-layer lipid coating, which includes lipid extract of peloids, oppositely charged molecules of which are placed on surfaces of external and internal hydrophilic layers. Liposomal nanocapsule contains, %: water extract of peloids - 74%, lipid extract of peloids - 20%, vitamin E - 5%, stabiliser with phospholipid base- 1%.

EFFECT: invention ensures enhancement of medical-cosmetic effect of liposomal nanocapsule.

1 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmacology and represents a pharmaceutical composition for integrated treatment of ocular surface diseases in the patients suffering primary open-angle glaucoma, on the basis of phospholipids and sulphated glycosaminoglycans, differing by the fact that composition represents a liposomal emulsion formed by phospholipids in the form of liposomes, of average particle size 0.05-0.22 mcm, and sulphated glycosaminoglycans with sulphated glycosaminoglycans presented by keratan sulphate sodium salt and chondroitin sulphate sodium salt with the ingredients of the composition taken in certain proportions, wt %.

EFFECT: invention provides preventing lachrymal production from decreasing, reducing tear evaporation, as well as avoiding pathological changes in conjunctival and corneal epithelial cells.

5 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Device, moving above patient with bright white light, photographs, registers and transmits onto display screen total area of wound surface of burns, including numerical ratio in percent, with possibility of enlarging the most affected sites, for logging and monitoring dynamics of wound surface therapy. Boundaries of affection degrees are determined under intensive blue colour. Depending on affection degree specialist selects therapy for each section. Depth of skin and organ affection is also determined by device by means of ultrasonic scanner and in case of necessity depth of burn affection is displayed on monitor in two-dimensional image and snapshots for comparative dynamics of recovery are made. After determining area and degree of affection fine-aerosol of antiseptic preparation is dispersed for quick reduction of wound surface temperature and prevention of infectious complications. After application of antiseptic preparation above entire wound surface performed is phototherapy with blue spectrum with simultaneous air ventilation for reducing pain, lowing down temperature of wound surface, recovery of its microcirculation and air ablation of necrotic tissues. After required surgery medication with film-forming suspension is applied by device in form of fine aerosol, which again leads to reduction of burn surface temperature and prevents "greenhouse effect" of wound. After application of medication device switches on blue irradiators, spectrum of which reduces pain, restores microcirculation, activates medication and increases cell metabolism, simultaneous switching on of ultrasonic transmitter increases permeability of pores and membranes of skin and epithelium cells for medications. After the end of procedure air ventilation is switched on.

EFFECT: blue spectrum will make it possible to accelerate process of wound surface healing and will exclude secondary infection, ensure cytoprotective effect, activate exchange processes, improve blood supply of tissues at the level of microcirculation.

5 cl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to aerosol composition, suitable for application for treatment of bronchospasms and associated with them disorders, which contains therapeutically efficient amount of troventol, microground together with propellant and one or more pharmaceutically acceptable carrier. Composition preferably contains 40-640 mcg of troventol and carrier can be selected from surface-active substance, co-solvent, antioxidant and/or filling agent.

EFFECT: invention also relates to dosing inhalator which contains aerosol composition for treatment of bronchospasms and associated with them disorders.

22 cl, 6 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to ophthalmology. A pharmaceutical composition is applicable in ophthalmology and contains the non-steroid anti-inflammatory drug indometacin and a phospholipid agent of the nanoparticle size 10-30 nm herbal phosphatidylcholine, maltose in the following proportions, wt %: phosphatidylcholine 20-43, maltose 55-78, indometacin 2-8. The indometacin and soya phospholipid composition represents a lyophilised powder.

EFFECT: invention provides prolonged storage stability of the composition.

2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed are: composition, which contains β2-agonist, except formoterol and salmoterol, and antagonist of muscarinic receptors M3, which represents 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxy-propyl)-1-azoniumbicyclo[2.2.2]octane in form of salt with anion X, which represents pharmaceutically acceptable anion of mono- or polyvalent acid (aclinidium) and its application for obtaining medication for simultaneous, joined, separate or successive introduction for treatment of respiratory disease, reacting to M3 antagonism (versions), product, set, package, including said combination and respective treatment method.

EFFECT: claimed composition does not give traditional for combination of β2-agonist and antagonist of muscarinic receptors M3 side effects (tachycardia, palpitation, complaints of pains in angina pectoris, arrhythmias) and can be used for treating patient with earlier acquired heart disease or state, which can be aggravated by tachycardia).

19 cl, 4 dwg, 1 tbl

Up!